NovoLog insulin aspart APPROVED
Drug Profile
ModalityPeptide
RouteSC
Therapy AreaCVRM
Launch2000-06-07
US LOE2020-01-01
Peak Sales Est$3000M
Formulations[{"id":"novolog-sc","notes":"Rapid-acting mealtime insulin","route":"SC","device":"FlexPen, FlexTouc
Companies
NVO (ORIGINATOR)100%
Mechanism: Insulin analog
Expert: Recombinant insulin analog with modified amino acid sequence or formulation to optimize pharmacokinetic profile for basal, prandial, or combination glycemic control.
Everyday: A modified version of insulin that helps the body use blood sugar for energy, designed to work faster or longer than natural insulin.
Targets: ["INSR"]
Revenue History
PeriodRevenue ($M)
2025$1,600M
Data from Supabase · Updated 2026-03-24